期刊文献+

转氨酶正常或低于正常值2倍以下慢性乙型肝炎病毒感染者治疗问题 被引量:7

暂未订购
导出
摘要 转氨酶正常或低于正常值2倍以下HBV感染者治疗问题已成为临床关注的热点。既往和更新版的国际、国内乙型肝炎相关指南对ALT正常或低于正常值2倍以下的HBV感染者,包括免疫耐受期、非活动性HBV携带者、非活动性HBsAg携带者因抗病毒治疗效果极差,故不予推荐抗病毒治疗。肝硬化患者,只要能检出HBVDNA,不论ALT或AST是否升高,应给予核苷(酸)类似物抗病毒治疗。笔者认为临床工作中对持续HBV DNA阳性,即使转氨酶正常或低于正常值2倍以下的HBV感染者,只要临床上有肝纤维化的证据,如影像学检查(B超、CT、MRI)提示脾脏肿大、血小板降低,其原因只能用HBV感染解释的,尤其对年龄在40岁以上或接近40岁年龄段的HBV感染者均应积极抗病毒治疗。慢性HBV携带者无需免疫治疗。本文还对慢性HBV携带者提出了若干建议,目的是普及乙型肝炎知识,提高认知程度,加强依从性教育。
作者 聂青和
出处 《实用肝脏病杂志》 CAS 2013年第4期293-295,共3页 Journal of Practical Hepatology
  • 相关文献

参考文献19

  • 1慢性乙型肝炎防治指南(2010年版)[J].实用肝脏病杂志,2011,14(2):81-89. 被引量:436
  • 2Ganem D,Prince AM. Hepatitis B virus infection-natural histo- ry and clinical consequences. N Engl J Med,2004,350(ll): 1118-1129.
  • 3Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int,2009,29 (Suppl 1 ):100-107.
  • 4McMahon BJ.The natural history of chronic hepatitis B virus infection. Hepatology,2009,49(5 Suppl):S45-55.
  • 5Hui CK,Leung N,Yuen ST,et al Study Group. Natural history and nese chronic hepatitis B patients Hepatology, 2007,46( 2 ):395-401. Hong Kong Liver Fibrosis disease progression in Chi- in immune-tolerant phase.
  • 6Lok AS,McMahon BJ. Chronic hepatitis B: update 2009. Hep- atology, 2009,50(3 ):661-662.
  • 7Chu CM,Liaw YF. HBsAg seroclearance in asymptomatic carri- ers of high endemic areas:appreciably high rates during a long-term follow-up. Hepatology,2007,45(5):l187-1192.
  • 8Chu CM,Hung SJ,Lin J,et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med,2004,116(12):829-834.
  • 9Park BK,Park YN,Ahn SH,et al. Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol, 2007,22(3 ):383-388.
  • 10European Association For The Study Of The Liver. EASL clin- ical practice guidelines:Management of chronic hepatitis B virus infection. J Hepatol,2012,57(1):167-185.

二级参考文献9

  • 1Suk FM, Lin MH, Newman m, Pan S, Chert SH, Liu JD, Shih C.Replication advantage and host factor-independent phenotypes attributable to a common naturally occurring capsid mutation(I97L) in human hepatitis B virus. J Virol 2002;76:12069-12077.
  • 2Asselah T,Martinot M,Cazals-Hatem D,Boyer N,Auperin A,Le Breton V, Erlinger S, Degott C, Valla D, Marcellin P.Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels. J Viral Hepat 2002;9:29-35.
  • 3Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P,McGarvey MJ, Makris A, Thomas HC. Mutation preventing for mutation of e antigen in patients with chronic HBV Lufection.Lancet 1989;Ⅱ:585-591.
  • 4Alexolooulou A, Karayiannis P, Hadziyannis SJ, Aiba N, Thomas HC.Emergence and selection of HBV variantd in an anti-HBe positive patient persistently infected with quasispecies.J Hepatol 1997;26:748-753.
  • 5Ling K, Mutimer D, Ahmaed M, Boxall EH, Elias E, Dusheiko GM,Harrison TJ. Selection of nutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine.Hepatology 1996;24:711-713.
  • 6Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW.Lamivudine resistance in immunocompetent chronic hepatitis B-incidence and patterns. J Hepatol 1997;26:1393-1395.
  • 7Thursz MR,Thomas HC. Host factors in chronic viral hepatitis.Semin Liver Dis 1997;17:345-350.
  • 8Thursz MR,Kwiatkowshi D,Allsopp CE,Greenwood BM, Thomas HC, Hill AV. Association between an MHC class Ⅱ allele and clearance of hepatitis B virus in the Ganbia.N Engl J Med 1995:332:1065-1069.
  • 9Lindemann M,Barsegian V,Siffert W,Ferencik S,Roggendorf M,Grosse-Wilde H. Role of G protein beta3 subunit C825T and HLA class Ⅱ polymorphisms in the immune response after HBV vaccination. Virology 2002;97:245-252.

共引文献462

同被引文献62

引证文献7

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部